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Objectives. To describe the pathophysiological mechanisms by which obesity increases the propensity to thrombosis, the
leading cause of death in the Western World, with particular emphasis on the role of inflammation, oxidative stress,
dyslipidaemia, insulin resistance and the coagulation cascade.
Design. Review article.
Materials and methods. Medline (1966e2005) and Cochrane library review of literature examining the relationship
between obesity and thrombosis. Search terms included obesity, overweight, body mass index, thrombosis, cardiovascular
disease, venous thromboembolism, peripheral arterial disease, and coronary heart disease.
Results. Obesity is an important and growing public health issue that is estimated to affect more than half of the UK adult
population. Obesity, in particular central (visceral) obesity, is associated with significant, and largely preventable, morbid-
ity and mortality including an increased incidence and prevalence of arterial and venous thrombotic events. The various
mechanisms by which obesity may cause thrombosis include: the actions of so-called adipocytokines from adipose tissue, e.g.
leptin and adiponectin; increased activity of the coagulation cascade and decreased activity of the fibrinolytic cascade;
increased inflammation; increased oxidative stress and endothelial dysfunction; and disturbances of lipids and glucose
tolerance in association with the metabolic syndrome.
Conclusions. Obesity appears to be associated with thrombosis via several mechanisms. These pro-thrombotic factors are
all improved by weight loss.
Keywords: Obesity; Thrombosis; Leptin; Adiponectin; Venous thromboembolism; Metabolic syndrome.Introduction
Two-thirds of all men and half of all women in
England (equivalent to approximately 24 million peo-
ple) are either overweight or obese.1 In England, obesity
accounts for approximately 18 million days of sickness
absence and 30,000 premature deaths each year.2 It is
estimated that the annual cost of treating obesity in
the UK is £500 million and the wider costs to the econ-
omy in terms of lower productivity and lost output
are £2 billion each year.2
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creased risk of coronary heart disease (CHD), periph-
eral arterial disease (PAD), stroke (CVA), and venous
thromboembolism (VTE).3e6 However, it remains to
be determined whether obesity is a truly independent
risk factor or acts through its association with several
other well-known cardiovascular risk factors (such as
insulin resistance/diabetes and dyslipidaemia). Obe-
sity also plays a central role in the development of
the metabolic syndrome, a cluster of cardiovascular
risk factors, which leads to an approximately 3-fold
risk of CHD and CVA.7
This article reviews what is currently known about
the pathophysiological mechanisms by which obesity
increases this propensity to thrombosis. In particular,
we discuss the role of inflammation, oxidative stress,
dyslipidaemia, insulin resistance, as well as direct
effects on the coagulation cascade.rved.
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We performed aMEDLINE (1966e2005) and Cochrane
library search looking for articles relating to the rela-
tionship between obesity, overweight and thrombosis.
These terms were linked with the following: coagula-
tion, thrombosis, fibrinolysis, cardiovascular disease,
coronary heart disease, stroke, peripheral vascular
disease and peripheral arterial disease, deep venous
thrombosis and venous thromboembolism. Further
articles were identified by following MEDLINE links,
by cross-referencing from the reference lists of major
articles and by following citations for these studies.
Results
The anatomy of obesity and cardiovascular risk
Obesity is defined as an excess of body fat and usu-
ally described by the body mass index (BMI) which
is calculated as the square of weight/height. The
World Health Organization (WHO) definition of
overweight is BMI> 25 kg/m2 and of obesity
BMI> 30 kg/m2. Two patterns of obesity have
been distinguished for the purposes of risk factor
assessment; namely, central (visceral) obesity and
peripheral obesity. Central obesity is defined as de-
position of fat around the trunk and in the visceral
adipose tissue. It is more common in men and car-
ries a higher risk of CHD, as well as various meta-
bolic derangements including dyslipidaemia and
glucose intolerance.4,8 Peripheral obesity is accumu-
lation of fat predominantly in the gluteo-femoral
area. It is more common in women and is less
strongly associated with cardiovascular risk.
The use of BMI alone as a marker of overweight and
obesity is limited for, although it correlates well with
total body fat content in adults, it fails to consider the
distribution of that fat.9 In view of the relationship
between central obesity andCHD, othermethods of de-
fining obesity have been used; for example, the waist
circumference (WC) and waist-to-hip ratio (WHR).
Men with a WC of >102 cm (>40 inches) and women
with a WC> 88 cm (>35 inches) have a higher risk of
CHD, and a WHR of >0.92 carries a nearly 3-fold
increased risk.9
The adipocyte and thrombosis
Adipose tissue is not only an energy storage tissue,
but also a metabolically active organ secreting hor-
mones, cytokines and growth factors that act in an
autocrine, paracrine or endocrine manner (Table 1).Eur J Vasc Endovasc Surg Vol 33, February 2007These moieties influence and help control energy
homeostasis, glucose and lipid metabolism, and vas-
cular homeostasis.10,11
Leptin
Although expressed in many tissues including mus-
cle, placenta and gastric epithelium, leptin is predom-
inantly produced and secreted from adipose tissue.
The majority of leptin studies have been performed
on animals. There is much evidence supporting the
theory that leptin acts via the hypothalamus to
suppress food intake and to increase energy expendi-
ture by modulating glucose and fat metabolism, and
enhancing thermogenesis.10 Leptin also has direct ef-
fects on many peripheral tissues, including muscle
and pancreatic beta cells.10
Hyperleptinaemia has been implicated in the
development of insulin resistance,12,13 and carries an
increased incidence of ischaemic stroke and acute
myocardial infarction (MI), independent of other
risk factors.14 To our knowledge, there are no pub-
lished studies examining the relationship between
leptin and VTE or PAD.
Most obese people have high circulating leptin
concentrations that should decrease caloric intake,
through a reduction in appetite and also increased
energy expenditure.15 It is, therefore, generally ac-
cepted that the overweight and obese are insensitive
to these effects of blood-borne leptin.10,16 Serum leptin
concentrations decrease following weight loss due to
dieting.11 Leptin levels in the cerebrospinal fluid of
obese patients are generally much lower than serum
levels suggesting that leptin is transported through
the blood-brain barrier via a saturable transport
system.17,18 Leptin resistance could, therefore, be
caused by abnormalities in that system, in the leptin
receptor, or in post-receptor signalling mechanisms.10,16
The leptin receptor is present in many tissues, including
platelets.12,19 Leptin promotes human platelet aggrega-
tion by potentiating the normal platelet response to its
agonists adenosine diphosphate and thrombin. This
has recently been suggested as a mechanism for acute
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225Obesity and Thrombosisthrombotic events in obesity.19,20 Further data is
needed on the concept of leptin resistance, for example,
whether it is selective and not affecting all tissues.
Leptin secretion is increased by tumour necrosis factor
(TNF)-a and prolonged hyperinsulinaemia, as found in
insulin resistance.10,12 Leptin also increases the synthe-
sis of C-reactive protein (CRP) by acting on interleukin
(IL)-6 receptors in the liver, thus possibly contributing
to the chronic inflammatory state of obesity.21
Adiponectin
Adiponectin is expressed only in adipocytes and
accounts for 0.01% of total plasma protein.12 In con-
trast to the other proteins secreted by adipose tissue,
circulating adiponectin levels are negatively correlated
with measures of obesity, and increase with weight
loss.16,22 Low levels of adiponectin are associated
with CHD, and various cardiovascular risk factors
including glucose intolerance, type 2 diabetes, and
hypertriglyceridaemia.10,16,22,23 To our knowledge,
there are no studies examining the relationship
between adiponectin and VTE or PAD. Adiponectin
levels are also negatively correlated with CRP, IL-6,
and plasminogen activator inhibitor (PAI)-1 levels.24,25
Adiponectin gene expression and secretion are in-
hibited by TNFa and IL-6.16,22 Adiponectin mimics
many metabolic effects of insulin and its main targets
are, therefore, skeletal muscle and the liver.26 In the
former, it stimulates glucose use and oxidation of fatty
acids, and in the latter, it increases insulin sensitivity
and fatty acid oxidation and reduces hepatic glucose
output.10,22,23,26 In addition, adiponectin is believed
to protect against cardiovascular disease by accumu-
lating in the wall of injured vessels and exerting
powerful anti-atherogenic and anti-inflammatory
actions.16,27,28 Specifically, it prevents macrophages from
producing TNFa and becoming ‘foam’ cells, inhibits
TNFa-induced leucocyte adhesion to endothelial cells,
increases the production of nitric oxide, and inhibits pro-
liferation and migration of smooth muscle cells.10,22,25,28
Resistin
Resistin is themost recently discovered, so-called, ‘adi-
pocytokine’. It is found at increased levels in obesemice
and may induce insulin resistance and raised CRP
levels.12,22,25 At the present time, the pathophysiologi-
cal role of resistin in human obesity remains uncertain.
The relationship between obesity and coagulation
and fibrinolysis (Fig. 1)
Plasminogen activator inhibitor-1
PAI-1 inhibits tissue plasminogen activator (tPA),
which cleaves plasmin from plasminogen and is,therefore, the primary physiological inhibitor of fibri-
nolysis in vivo.10 PAI-1 is produced in several tissues
including liver, spleen and adipocytes.29 Elevated
PAI-1 levels compromise the normal clearance of
fibrin and consequently promote thrombosis.29,30
PAI-1 levels are positively correlated with obesity
(measured by BMI, WC and WHR), insulin resistance,
and triglyceride levels,29e31 and PAI-1 levels are signi-
ficantly reduced by weight loss in obese individuals.10
High PAI-1 concentrations have been found in pa-
tients with recent MI, chronic CHD, PAD, DVT, and
CVA.29,32e34 Several factors increase PAI-1 expression
and synthesis in adipose tissue, including free fatty
acids, triglycerides, insulin, TGFb, angiotensin II,
CRP and TNFa.10,29e31 Thus, the increased levels of
PAI-1 found in obesity may predispose to micro- and
macro-vascular, arterial and venous, thrombosis.31
Fibrinogen
Hyperfibrinogenaemia is associated with an increased
prevalence and incidence of primary and recurrent
CHD, CVA, PAD and VTE,35e38 and correlates with
measures of obesity in several studies, especially in
women.38,39 Fibrinogen promotes arterial and venous
thrombosis through increased fibrin formation, plate-
let aggregation and plasma viscosity; and promotes
atherosclerosis through vascular smooth muscle and
endothelial cell proliferation.37
Tissue factor (TF)
The coagulation cascade is initiated when TF is
exposed to blood and binds with factor VIIa. Obese
patients exhibit increased TF-mediated coagulation,
with raised adipocyte and monocyte TF expression
secondary to elevated levels of CRP, TGFb, TNFa,
angiotensin II and insulin.29,40
Factor VII and VIII
High factor VII and factor VIII levels correlate with
measures of obesity,37,39 and an increased risk of
CHD and stroke in some, but not all, studies.41e44 Fac-
tor VIII, but apparently not VII, is strongly associated
with an increased risk of VTE.37,45 High triglycerides
and low high density lipoprotein (HDL) cholesterol,
the most common lipid disturbances found in obesity,
are also found with high factor VII and VIII levels.38,41
The relationship between obesity, inflammation
and thrombosis
Obesity can be considered a chronic, low-grade in-
flammatory state, as demonstrated by increased levels
of the pro-inflammatory cytokines IL-6 and TNFa, andEur J Vasc Endovasc Surg Vol 33, February 2007
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Fig. 1. Obesity and the coagulation cascade: the different pathways in the coagulation and fibrinolytic cascades that may be
affected by obesity.acute phase proteins such as CRP. This pro-inflamma-
tory state is attenuated by weight loss.44,45 As well as
its direct effects, inflammation may cause thrombosis
indirectly by inducing oxidative stress and endothe-
lial dysfunction.46
C-reactive protein (CRP)
Elevated CRP is a powerful marker of increased athe-
rothrombotic events,40,47 correlates positively with
BMI, and visceral fat accumulation,40,48 and may con-
tribute to thrombosis via several mechanisms. Specif-
ically, it may (a) increase endothelial adhesion
molecule expression, (b) stimulate macrophages to
produce cytokines, such as IL-6 and TNFa, which
may render an otherwise stable atherosclerotic plaque
vulnerable to rupture and (c) induce TF production by
monocytes.25,46,49e51
Interleukin-6 (IL-6)
IL-6 is produced by adipose tissue, monocytes and
macrophages, endothelial cells, and skeletal and
smooth muscle cells. Up to one-third of circulatingEur J Vasc Endovasc Surg Vol 33, February 2007IL-6 comes from adipose tissue.10,40 IL-6 production
is increased by IL-1 and TNFa, and is associated
with thrombotic cardiovascular events.52 IL-6 levels
are positively associated with BMI, WC and WHR,
and also with measures of insulin resistance.4,48 IL-6
levels decrease with weight loss.52 IL-6 increases
plasma lipids and glucose by inducing insulin resis-
tance through decreasing insulin signalling in peri-
pheral tissues.10,12 IL-6 may also promote thrombosis
indirectly through increasing platelet count and ag-
gregation, hepatic synthesis of fibrinogen and CRP,
endothelial adhesion molecule expression, and
decreasing adiponectin secretion.16,52
Tumour necrosis factor-a (TNFa)
Adipocyte TNFa secretion is positively correlated
with obesity and reduces with weight loss.46,52 Adipo-
cyte TNFa receptor expression also correlates with
obesity,10,46 and may contribute to insulin resistance
directly by inhibiting insulin receptor activity and
signalling, and indirectly by increasing serum non-
esterified fatty acids (NEFAs).10,21,22,29 NEFAs induce
227Obesity and Thrombosisinsulin resistance in a variety of tissues. TNFa in-
creases the hepatic synthesis of NEFAs and also re-
duces the uptake and storage of NEFAs in adipose
tissue.10,50 TNFa stimulates leptin production and
reduces adiponectin secretion from adipose tissue, in-
duces PAI-1 expression in adipose tissue, and pro-
motes endothelial adhesion molecule expression.10,16
The relationship between obesity, oxidative stress,
endothelial dysfunction and thrombosis (Fig. 2)
Oxidative stress
Oxidative stress is defined as a state where the normal
balance between the body’s pro-oxidant and anti-
oxidant systems is disturbed in favour of oxida-
tion.53,54 Oxidative stress from reactive oxygen species
production promotes endothelial dysfunction, platelet
aggregation, and thrombus formation.55 It also
impairs both pancreatic insulin secretion and, in
rodent studies, it reduces glucose transport in muscle
and adipose tissue.56 F2-isoprostanes are products of
the peroxidation of arachidonic acid, catalysed by
free radicals.53,57 Measurement of F2-isoprostanes is
currently the most accurate method available toquantify oxidative stress in humans.58 Increased
CRP is also found with significant elevations in
isoprostanes.53,57 F2-isoprostanes themselves induce
vasoconstriction and can amplify the response of
human platelets to other agonists.59,60 Enhanced iso-
prostane formation is strongly correlated with increas-
ing BMI and WHR.59,60 Many of the metabolic
abnormalities found with obesity are also associated
with increased oxidative stress.60 NEFAs, TNFa, and
oxidised LDL (low density lipoprotein) cholesterol
may all increase the production of reactive oxygen
species, superoxide and H2O2 in the endothelium.
46,61
Reactive oxygen species themselves serve as a precur-
sor to oxidised LDL formation, essential to the devel-
opment of atherosclerotic lesions.46 Protein glycation
and glucose autoxidation in hyperglycaemia also
cause oxygen free radical formation.54 HDL particles,
which are commonly reduced in obesity-associated
dyslipidaemia, have anti-inflammatory and potent
anti-oxidative activity, and indeed dyslipidaemia has
been found to increase isoprostanes.54,60 As men-
tioned previously, inflammation and raised levels of
CRP, IL-6 and TNFa also contribute to oxidative stress
in obesity. This is consistent with studies that have
found elevated levels of F2-isoprostanes in severalAdipose
Tissue
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Fig. 2. Oxidative stress and obesity: how obesity may lead to oxidative stress.Eur J Vasc Endovasc Surg Vol 33, February 2007
228 K. A. L. Darvall et al.inflammatory diseases.57 Furthermore, antioxidant
defence mechanisms are reduced in obesity, including
decreased erythrocyte glutathione and glutathione
peroxidase.62
Endothelial dysfunction
Endothelial dysfunction is characterised by a distur-
bance in the normal balances between vasocon-
strictors and vasodilators, growth promotors and
inhibitors, pro- and anti-atherogenic processes, and
pro- and anti-coagulant factors.61 Endothelial dys-
function is central to the development and progres-
sion of atherosclerosis, and enhances the risk of
future cardiovascular events.61 Endothelial dysfunc-
tion is present in overweight patients, especially those
with visceral obesity and insulin resistance, and
weight loss leads to an improvement in endothelial
function.52,61,63 As described above, low levels of adi-
pocyte-derived circulating and intra-mural adiponec-
tin may favour endothelial damage; possibly through
a decrease in nitric oxide (NO) production in associa-
tion with an increase in reactive oxygen species.55 NO
not only reduces vascular smooth muscle cell migra-
tion and growth, platelet aggregation, monocyte and
macrophage adhesion, and inflammation, but also
causes vasodilatation.61 Decreased NO production
may therefore contribute to increased platelet activa-
tion and arterial thrombosis, as well as increased
atherogenesis.
Renin-angiotensin system
In obese rodents, the renin-angiotensin system (RAS)
is up-regulated in adipose and non-adipose tissue.64
Renin, angiotensinogen, angiotensin (AT) I and II,
and angiotensin converting enzyme (ACE) are all pro-
duced by adipocytes.10 AT II promotes tissue superox-
ide production, increases LDL uptake by macrophages
and, in vessel walls, has significant pro-inflammatory
actions.65 Specifically, AT II increases the production
of reactive oxygen species, inflammatory cytokines
and adhesion molecules leading to vasoconstriction,
vascular smooth muscle cell proliferation, and athero-
sclerotic plaque destabilization.64,65
The relationship between obesity, the metabolic syndrome
and thrombosis
The metabolic syndrome is defined as the presence of
three or more of:66
(1) Fasting glucose> 6.1 mmol/L (>110 mg/dL)
(2) Triglycerides> 1.69 mmol/L (>150 mg/dL)Eur J Vasc Endovasc Surg Vol 33, February 2007(3) HDL cholesterol< 1.04 mmol/L (<40 mg/dL) in
men; and <1.29 mmol/L (<50 mg/dL) in women
(4) Blood pressure> 130/85 mmHg
(5) Abdominal obesity: WC> 102 cm (40 inches) in
men; and >88 cm (35 inches) in women
Patients with the metabolic syndrome have a 3-fold
increased risk of CHD and stroke.7,67 Overall, around
a quarter of adults in Europe and North America have
the metabolic syndrome, rising to around 40% of those
aged over 40 years in one study.68e71 The Women’s
Ischemia Syndrome Evaluation (WISE) study of 780
women referred for coronary angiography found that
76% of obese, compared with 28% of normal BMI,
subjects had the metabolic syndrome or diabetes.67
Significantly, weight loss usually improves all aspects
of the metabolic syndrome.7,72
The relationship between obesity, insulin resistance
and thrombosis
Insulin resistance leads to hyperinsulinaemia due to
the inability of insulin to promote glucose uptake in
skeletal muscle and adipose tissue, and to suppress
hepatic glucose production.61 Fasting insulin levels
are strongly and directly correlated with BMI and
WHR, and insulin sensitivity improves with weight
loss.7
The adipocyte, as discussed previously, synthesises
and releases TNFawhich causes defects in insulin sig-
naling leading to insulin resistance.29 Leptin regulates
the intracellular utilization of fatty acids for energy,
and therefore leptin resistance results in intracellular
accumulation of triglycerides in skeletal muscle which
decreases insulin-mediated glucose disposal. Reduced
production of adiponectin in patients with obesity has
also been associated with insulin resistance.73
In obesity, the adipocytes release large amounts of
NEFAs and it is thought that this may play a major
role in insulin resistance. Indeed because of their ex-
cessive availability they will be used preferentially
for energy production. Large amounts of NEFAs in-
hibit the action of insulin in peripheral tissues, and
they also induce hepatic synthesis of clotting factors
and can promote aggregation of platelets.74
Fasting insulin level is an independent risk factor
for CHD,75,76 and PAD is more prevalent in diabetic/
impaired glucose tolerance subjects, compared to
normal glucose tolerance subjects.77 Atherothrombotic
complications in insulin resistance are partly attrib-
uted to the pro-thrombotic state including endothelial
activation, hyperactivity of platelets, hypercoagul-
ability and hypofibrinolysis.74 Plasma insulin levels
229Obesity and Thrombosisincrease circulating PAI-1 levels, and show significant
positive correlations with factor VII, fibrinogen and
TF.75,76 Hyperglycaemia as previously mentioned can
cause reactive oxygen species generation and oxida-
tive stress.54
The relationship between obesity, dyslipidaemia and
thrombosis (Fig. 3)
Reduction of plasma HDL cholesterol is the most
common lipid disturbance in obese subjects and is
due in part to hypertriglyceridaemia, although low
concentrations may often be seen without raised tri-
glycerides in obese subjects.50 When present, hypertri-
glyceridaemia is accompanied by increases in small
dense LDL, which is strongly atherogenic.50
The high levels of NEFAs released in obesity, as
well as inducing insulin resistance, are metabolised
by the liver to increase hepatic synthesis of triglycer-
ides and VLDL (very low density lipoprotein).50,54
High circulating levels of VLDL reduce HDL concen-
tration and increase small dense LDL.12,54 Patients
who lose weight show a decrease in serum LDL and
triglyceride concentrations, and an increase in serum
HDL concentrations.7
Lipid disorders are also accompanied by platelet
hyperactivity, hypercoagulability with increased fac-
tor VII, and hypofibrinolysis with increased PAI-1.78
High plasma levels of triglycerides increase oxidativestress by increasing production of superoxide. The in-
creased flux of NEFAs from the adipocytes increases
TF and PAI-1 levels and enhances platelet aggrega-
tion; all obviously promoting thrombosis.50 Lipopro-
tein(a) levels are raised in obesity, particularly when
associated with hyperglycaemia. Lipoprotein(a) has
LDL-like properties and is structurally similar to
plasminogen. It therefore inhibits plasminogen bind-
ing to the endothelial cell and interferes with the
generation of plasmin. Lipoprotein(a) levels are raised
in patients with CHD and in those with intermittent
claudication.79 Lipoprotein(a) is therefore both athero-
genic and thrombogenic. Prothrombin levels and
vitamin K-dependent coagulation factor levels are in-
creased with hyperlipidaemia.38,41 High triglycerides
and low HDL have also been associated with insulin
resistance.75 HDL particles possess potent antioxida-
tive activity and therefore oxidative stress is increased
by the low HDL found with obesity.54
Obesity and coronary thrombosis
Acute coronary syndromes (ACS) are usually trig-
gered by rupture or erosion of an atheromatous
plaque.51 When the plaque ruptures, endothelial TF
is exposed to blood and activates the coagulation cas-
cade causing thrombus formation.51 Obesity, acting
through hyperlipidaemia and inflammation, may

























Fig. 3. Obesity, dyslipidaemia and thrombosis: how obesity and its effects on lipid metabolism may contribute to
thrombosis.Eur J Vasc Endovasc Surg Vol 33, February 2007
230 K. A. L. Darvall et al.to rupture.40,50,51 ACS is independently and positively
correlated with elevated CRP.80 In obese patients there
is increased expression of TF, enhanced platelet acti-
vation, and elevated PAI-1, consequently affecting
the initiation and progression of the intra-luminal
thrombus formed after coronary plaque rupture.29,60
Perhaps for these reasons, obesity shows a strong
association with ACS independent of many other
cardiovascular and metabolic risk factors.80
Obesity and venous thromboembolism
Numerous studies have shown a clear relationship be-
tween obesity and the risk of idiopathic VTE (deep
vein thrombosis [DVT] and pulmonary embolism
[PE]), independent of other recognised risk factors
(Odds Ratios [OR] of 2.26 and 2.42 in two separate
studies comparing BMI >30 with BMI <25).5,6,81,82
Obese patients are also more likely to develop the
post-thrombotic syndrome following DVT.83 The
obese have chronically raised intra-abdominal pres-
sure and decreased blood velocity in the common
femoral vein.84 Inactivity, poor gait, as well as other
life-style characteristics and co-morbidity, may further
impair venous return from the lower limbs.
Obesity and stroke
Several large cohort studies have found a relationship
between obesity and the risk of ischaemic stroke in
men and in women (in three separate studies, an OR
of 1.95 was found in men when BMI >30 was com-
pared with BMI <23; an OR of 1.90 was found in
women when BMI 29e32 was compared with BMI
<21; and an OR of 3.0 was found when comparing
the 4th quartile of WHR in men and women, with
the 1st quartile).3,36,50,85e87 Increased risk of athero-
sclerosis, thrombotic potential and blood pressure
are likely contributory factors. High leptin levels are
associated with stroke (both haemorrhagic and ischae-
mic) independent of age and hypertension in both
men and women.14
Obesity and peripheral arterial disease
There are few studies examining the relationship be-
tween obesity and PAD. Some cross-sectional and
prospective cohort studies have found obesity to be
a risk factor for development of PAD, whereas others
have found an association to be lacking.88e90 It is sug-
gested that this may be due to the higher prevalence
of PAD in elderly males and in cigarette smokers;
elderly males show a weaker relationship betweenEur J Vasc Endovasc Surg Vol 33, February 2007obesity and cardiovascular disease, and smokers
tend to have lower BMI than non-smokers.91 A recent
cross-sectional study revealed a significant positive
relationship between WHR and PAD prevalence, but
not with BMI.92 Obese patients also have an increased
prevalence of effort-related calf pain, which improves
after weight loss; and patients with PAD are less likely
to have progression of their disease, and more likely
to have symptomatic improvement if they lose
weight.88,93
Although the mechanisms by which obesity may
cause PAD may be similar to CHD, the two disease
states do have different risk profiles, for example,
cigarette smoking is more strongly associated with
development of PAD than CHD.94 Similarities are
suggested by observations that high fibrinogen levels,
increased markers of systemic oxidative stress,
markers of impaired fibrinolysis, and increased in-
flammatory markers are also found in PAD.95e97
However, there remains a significant gap in our
knowledge regarding the interrelationship of obesity
and PAD, including aneurysms. Future studies
should aim to ascertain the increased risk (if any) of
developing PAD in obesity, particularly visceral obe-
sity; the effect of obesity on complications of PAD,
e.g. rupture of abdominal aortic aneurysm (AAA),
critical limb ischaemia, requirement for major and mi-
nor limb amputations, and need for any interventions;
the mechanisms by which obesity may cause PAD;
and the benefits of weight reduction on preventing
development of PAD, and progression of existing
PAD. These areas should be addressed as a matter
of urgency.
Conclusion
Obesity appears to be independently associated with
both arterial and idiopathic venous thrombotic events.
There are several mechanisms through which obesity
can mediate its effects. The pro-thrombotic factors as-
sociated with obesity have been shown to improve
with weight loss indicating that obesity is a modifiable
risk factor for thrombosis.
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